查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961288

多西他赛三水合物原料药市场－全球产业规模、份额、趋势、机会、预测：按产品类型、应用、最终用户、地区和竞争对手划分，2021-2031年

Docetaxel Trihydrate API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球多西他赛三水合物活性原料药市场预计将从 2025 年的 14.5 亿美元成长到 2031 年的 21.1 亿美元，复合年增长率为 6.45%。

该药物的活性成分是一种紫杉烷抗肿瘤药物，用于胃癌、前列腺癌、非小细胞肺癌和乳癌的化疗。它作为微管抑制剂，稳定细胞骨架，从而阻止细胞分裂并诱导细胞凋亡。市场成长的主要驱动力是全球癌症发生率的上升以及对有效治疗方法的需求。同时，原厂药专利到期促进了价格低廉的学名药的生产，从而增加了对这种重要化合物的需求。

市场概览
预测期 2027-2031
市场规模：2025年 14.5亿美元
市场规模：2031年 21.1亿美元
复合年增长率：2026-2031年 6.45%
成长最快的细分市场 製药公司
最大的市场 北美洲

儘管需求强劲，但市场仍面临许多挑战，包括供应链可靠性以及高活性化合物生产流程的复杂性，这些都可能导致产品短缺和供应不稳定。根据美国医疗保健系统药剂师协会 (ASHP) 的数据，2024 年医疗保健行业出现了创纪录的 323 种药品短缺，其中多西他赛等关键无菌注射剂受到衝击。这些供应中断凸显了供应链网路的脆弱性，并对全球市场的稳定扩张构成重大障碍。

市场驱动因素

多西他赛三水合物原料药市场的主要驱动力是全球目标癌症发生率的不断上升，包括乳癌、摄护腺癌和非小细胞肺癌。这导致对成熟化疗药物的需求增加。长期流行病学预测也支持这一成长趋势。世界卫生组织（WHO）在其2024年2月发布的题为《全球癌症负担》的新闻稿中指出，预计到2050年，全球新增癌症病例将超过3500万例，比2022年增长77%。在以多西他赛为标准治疗方案的适应症中，这趋势尤其显着。例如，美国癌症协会估计，2024年美国将新增310,720例侵袭性乳癌病例，凸显了该原料药物在一线和辅助性治疗中的持续需求。

此外，各国政府为改善癌症治疗的可及性所做的努力正在重塑市场格局，其途径是解决高活性化合物供应的薄弱环节。监管机构正在实施战略框架，并促进与生产商的合作，以识别供应瓶颈并实现生产能力多元化，从而应对持续存在的供不应求。一个值得关注的例子是欧盟委员会于2024年4月启动的「重要药物联盟」。该联盟汇集了约250个成员组织，旨在加强供应链并防止供不应求，为原料药生产商创造更稳定的环境，并确保患者能够获得挽救生命的治疗。

市场挑战

多西他赛三水合物原料药市场成长的主要障碍在于供应链的脆弱性和高活性药物原料药生产相关的技术复杂性。这种紫杉烷类化合物的生产需要专门的密闭设施和严格的品管。这些要求限制了能够生产该产品的製造商数量，从而造成供应瓶颈。因此，当物流中断影响到这个脆弱的供应链网络时，製造商无法迅速扩大生产规模以满足不断增长的全球需求，导致收入损失，并阻碍市场充分利用癌症发病率上升所带来的机会。

这些供应链功能障碍的影响十分严重，2024年美国国家综合癌症网络（NCCN）的调查结果就印证了这一点。 89%的受访癌症中心报告称，关键抗癌药物和辅助治疗药物出现短缺。这种普遍的供不应求迫使医疗机构限制剂量或将患者转为替代疗法，导致多西他赛的即时消耗量下降。最终，产品供应的持续不稳定正在破坏市场稳定，并显着减缓这种关键原料药的商业性扩张。

市场趋势

奈米技术药物递送系统的发展正在改变市场格局，这主要得益于製造商为降低传统溶剂型製剂的毒性所做的努力。诸如白蛋白结合型多西他赛奈米颗粒等创新技术因其无需预先使用皮质类固醇并能减少超敏反应而备受关注，而监管区域的战略许可协议进一步推动了这一趋势。例如，Zydus Life Sciences 在 2025 年 2 月发布的新闻稿《Zydus Life Sciences 获得美国抗癌药物许可》中宣布，美国对多西他赛注射剂的年商业性预计将达到约 53.1 万支，这体现了这些改良产品的商业潜力。

同时，抗体药物复合体（ADC）细胞毒性有效载荷生产过程的日益复杂化，正推动高活性药物原料药（HPAPI）的生产外包给专业的契约製造生产商。製药公司越来越倾向于利用专业化、高防护等级的合约研发生产机构（CDMO），而不是自建资本密集设施，这刺激了对生产能力的显着投资。例如，2025年6月，Piramal Pharma Solutions宣布投资9,000万美元扩建其美国原料药，旨在增强其HPAPI和ADC有效载荷连接子的商业化生产能力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球多西他赛三水合物原料药市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（纯度 99% 或更高，纯度低于 99%）
    • 依应用领域（肿瘤学、研发、其他）
    • 依最终用户（製药公司、研究机构、契约製造组织）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：多西他赛三水合物原料药北美市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲多西他赛三水合物原料药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区多西他赛三水合物原料药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东及非洲多西他赛三水合物原料药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美多西他赛三水合物原料药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球多西他赛三水合物原料药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Pfizer Inc
  • Accord Healthcare, Inc
  • Sandoz Group AG
  • Aurobindo Pharma Ltd Inc
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27653

The Global Docetaxel Trihydrate API Market is projected to expand from USD 1.45 Billion in 2025 to USD 2.11 Billion by 2031, registering a CAGR of 6.45%. This active pharmaceutical ingredient is a taxane-derived antineoplastic agent used in chemotherapy for gastric, prostate, non-small cell lung, and breast cancers, acting as a microtubule inhibitor that stabilizes the cellular cytoskeleton to halt cell division and trigger apoptosis. Market growth is largely driven by the increasing global prevalence of cancer and the need for effective therapeutic regimens, while the expiration of innovator patents has boosted the production of affordable generics and increased the volume requirements for this essential compound.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.45 Billion
Market Size 2031USD 2.11 Billion
CAGR 2026-20316.45%
Fastest Growing SegmentPharmaceutical Companies
Largest MarketNorth America

Despite strong demand, the market faces significant hurdles regarding supply chain reliability and the complexities involved in manufacturing high-potency compounds, which often lead to product scarcity and inconsistent availability. Data from the American Society of Health-System Pharmacists indicates that the healthcare sector experienced a record 323 active drug shortages in 2024, affecting critical sterile injectables like docetaxel. These interruptions demonstrate the vulnerability of the supply network and pose a major obstacle to the steady expansion of the global market.

Market Driver

The primary driver for the Docetaxel Trihydrate API market is the escalating global incidence of target cancer indications, including breast, prostate, and non-small cell lung malignancies, which necessitates higher production volumes of established chemotherapeutic agents. Long-term epidemiological projections confirm this surge, with the World Health Organization reporting in a February 2024 press release titled 'Global cancer burden growing' that over 35 million new cancer cases are anticipated in 2050, marking a 77% rise from 2022 levels. This trend is especially pronounced in indications where docetaxel is a standard treatment; for example, the American Cancer Society estimated that 310,720 new invasive breast cancer cases would be diagnosed in the United States in 2024, highlighting the enduring need for this API in first-line and adjuvant therapies.

Additionally, government initiatives aimed at improving access to cancer treatments are reshaping the market by targeting vulnerabilities in the supply of high-potency compounds. Regulatory authorities are implementing strategic frameworks and fostering collaboration with manufacturers to identify supply constraints and diversify production capabilities in response to persistent shortages. A notable instance is the European Commission's launch of the Critical Medicines Alliance in April 2024, which convened approximately 250 members to reinforce the supply chain and prevent scarcity, thereby creating a more stable environment for API producers and ensuring patient access to life-saving therapies.

Market Challenge

A major impediment to the growth of the Docetaxel Trihydrate API market is the combination of supply chain vulnerabilities and the technical complexity involved in manufacturing high-potency active pharmaceutical ingredients. The production of this taxane-derived compound demands specialized containment facilities and strict quality controls, requirements that limit the number of capable manufacturers and create supply bottlenecks. Consequently, when logistical disruptions impact this fragile network, manufacturers are unable to rapidly scale production to meet rising global demand, leading to revenue losses and preventing the market from fully capitalizing on increasing cancer rates.

The consequences of these supply chain failures are severe, as evidenced by the National Comprehensive Cancer Network's 2024 findings, where 89% of surveyed cancer centers reported shortages of key anti-cancer agents and supportive medications. Such widespread scarcity compels medical providers to ration doses or switch patients to alternative treatments, effectively lowering the immediate consumption of docetaxel formulations. Ultimately, the persistent unreliability of product availability destabilizes the market and significantly slows the commercial expansion of this critical API.

Market Trends

The market is being transformed by the development of nanotechnology-based drug delivery systems, as manufacturers strive to reduce the toxicity linked to traditional solvent-based formulations. Innovations such as albumin-bound docetaxel nanoparticles are becoming popular for their ability to eliminate the need for corticosteroid premedication and lower hypersensitivity reactions, a trend supported by strategic licensing agreements in regulated regions. Highlighting the commercial potential of these improved profiles, Zydus Lifesciences noted in a February 2025 press release titled 'Zydus Lifesciences Licenses Cancer Drug in US' that the US market for docetaxel injection sees an annual volume uptake of roughly 531,000 units.

Concurrently, there is a shift toward outsourcing to specialized High Potency Active Pharmaceutical Ingredient (HPAPI) contract manufacturers due to the growing complexity of producing cytotoxic payloads for antibody-drug conjugates (ADCs). Pharmaceutical innovators are increasingly utilizing Contract Development and Manufacturing Organizations (CDMOs) with niche high-containment infrastructure rather than investing in their own capital-intensive facilities, prompting significant investment in manufacturing capacity. For example, Piramal Pharma Solutions announced a $90 million investment in June 2025 to expand its US facilities, specifically aimed at enhancing commercial-scale capabilities for high-potency APIs and ADC payload-linkers.

Key Market Players

  • Pfizer Inc
  • Accord Healthcare, Inc
  • Sandoz Group AG
  • Aurobindo Pharma Ltd Inc
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

Report Scope

In this report, the Global Docetaxel Trihydrate API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Docetaxel Trihydrate API Market, By Product Type

  • Purity >= 99%
  • Purity < 99%

Docetaxel Trihydrate API Market, By Application

  • Oncology
  • Research and Development
  • Others

Docetaxel Trihydrate API Market, By End-User

  • Pharmaceutical Companies
  • Research Institutes
  • Contract Manufacturing Organizations

Docetaxel Trihydrate API Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Docetaxel Trihydrate API Market.

Available Customizations:

Global Docetaxel Trihydrate API Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Docetaxel Trihydrate API Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Purity >= 99%, Purity < 99%)
    • 5.2.2. By Application (Oncology, Research and Development, Others)
    • 5.2.3. By End-User (Pharmaceutical Companies, Research Institutes, Contract Manufacturing Organizations)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Docetaxel Trihydrate API Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Docetaxel Trihydrate API Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Docetaxel Trihydrate API Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Docetaxel Trihydrate API Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Docetaxel Trihydrate API Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Docetaxel Trihydrate API Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Docetaxel Trihydrate API Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Docetaxel Trihydrate API Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Docetaxel Trihydrate API Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Docetaxel Trihydrate API Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia Pacific Docetaxel Trihydrate API Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Docetaxel Trihydrate API Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Docetaxel Trihydrate API Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Docetaxel Trihydrate API Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Docetaxel Trihydrate API Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Docetaxel Trihydrate API Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Docetaxel Trihydrate API Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Docetaxel Trihydrate API Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Docetaxel Trihydrate API Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Docetaxel Trihydrate API Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. South America Docetaxel Trihydrate API Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Docetaxel Trihydrate API Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Docetaxel Trihydrate API Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Docetaxel Trihydrate API Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Docetaxel Trihydrate API Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Accord Healthcare, Inc
  • 15.3. Sandoz Group AG
  • 15.4. Aurobindo Pharma Ltd Inc
  • 15.5. Cipla Inc.
  • 15.6. Hikma Pharmaceuticals PLC
  • 15.7. Sun Pharmaceutical Industries Ltd.
  • 15.8. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer